9 completed, 3 unknown, 1 terminated. 13 Phase 3, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 13 | Completed 9, Unknown 3, Terminated 1 |
| Phase 2 | 1 | Completed 1 |
Follow fosamprenavir: new trials by email Literature Review of fosamprenavir trials Research Report on fosamprenavir
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Trial to Evaluate the Interest of a Reductive Anti Retroviral Strategy Using Dual Therapy Inspite of Triple Therapy triple therapy, dual therapy - HIV | Phase 3 | Completed | University Hospital, Tours | 224 | 2014-12-01 | 2025-12-26 |
| A Study in Underrepresented Patient Population or Regimen Tolerability: SUPPoRT Efavirenz 600mg, Boosted Lexiva - Human Immunodeficiency Virus Infections | Phase 3 | Completed | Georgetown University | 101 | 2008-07-01 | 2013-07-02 |
| HIV-1 Infection Study of Once a Day Versus Twice a Day Protease Inhibitor in Antiretroviral Treatment Naive Adults fosamprenavir/ritonavir - Infection, Human Immunodeficiency Virus I, HIV-1 Infection | Phase 3 | Completed | ViiV Healthcare | 212 | 2007-03-01 | 2012-06-07 |
| Clinical Trial of CNS-targeted HAART (CIT2) FDA Approved Antiretroviral Therapy (see list below) - HIV Infections | Phase 2 / Phase 3 | Completed | University of California, San Diego | 59 | 2007-03-01 | 2014-04-23 |
| A Study of an Investigational Regimen Combining FDA Approved HIV Drugs in HIV-Infected Subjects Half-boosted Fosamprenavir, Full Boosted Fosamprenavir - HIV Infection, Infection, Human Immunodeficiency Virus | Phase 3 | Completed | GlaxoSmithKline | 211 | 2006-05-01 | 2010-11-05 |
| Open Label Study of 908/RTV in Combination With Other PIs for the Treatment of Multi PI-Experienced HIV Subjects fosamprenavir/ritonavir (700mg/100mg BID), fosamprenavir/ritonavir (1400mg/100mg BID), fosamprenavir/lopinavir/ritonavir (1400mg/533mg/100mg BID) - HIV-1 | Phase 3 | Terminated | GlaxoSmithKline | 150 | 2005-03-01 | 2007-11-12 |
| Fosamprenavir Versus Other Protease Inhibitors Fosamprenavir - Infection, Human Immunodeficiency Virus I | Phase 3 | Completed | ViiV Healthcare | 314 | 2004-12-14 | 2018-04-18 |
| KALETRA Or LEXIVA With Ritonavir Combined With EPIVIR And Abacavir In Naive Subjects Over 48 Weeks LEXIVA (GW433908), Ritonavir, KALETRA - HIV Infection, Infection, Human Immunodeficiency Virus | Phase 3 | Completed | GlaxoSmithKline | 866 | 2004-05-01 | 2011-05-16 |
| Study to Explore Safety And Tolerability of Fosamprenavir With or Without Ritonavir in Combination With TRIZIVIR or COMBIVIR fosamprenavir, COMBIVIR, ritonavir - HIV Infections | Phase 3 | Completed | GlaxoSmithKline | 60 | 2002-01-01 | 2013-02-12 |
| A Study To Assess GW433908 (Fosamprenavir) Containing Regimens In HIV-1 Infected Subjects fosamprenavir (GW433908), ritonavir - Infection, Human Immunodeficiency Virus | Phase 3 | Completed | ViiV Healthcare | 753 | 2001-11-01 | 2013-04-19 |
| Comparison of Two Dosing Regimens of GW433908/Ritonavir Versus Lopinavir/Ritonavir for 48 Weeks in HIV Patients Who Have Taken Protease Inhibitors and Experienced Virological Failure Lopinavir/Ritonavir, Ritonavir, GW433908 - HIV Infections | Phase 3 | Unknown | GlaxoSmithKline | 330 | 2001-05-01 | 2005-06-24 |
| Comparison of GW433908/Ritonavir to Nelfinavir When Used With Abacavir and Lamivudine in Patients That Have Not Taken Antiretroviral Drugs Ritonavir, Abacavir sulfate, Nelfinavir mesylate - HIV Infections | Phase 3 | Unknown | Glaxo Wellcome | 624 | 2000-11-01 | 2005-06-24 |
| Comparison of GW433908 and Nelfinavir in HIV Patients Who Have Not Had Antiretroviral Therapy Abacavir sulfate, Nelfinavir mesylate, Lamivudine - HIV Infections | Phase 3 | Unknown | Glaxo Wellcome | 210 | 2000-11-01 | 2005-06-24 |
HIV Infections (7) · Infections (5) · Acquired Immunodeficiency Syndrome (4) · AIDS Dementia Complex (1) · Cognitive Dysfunction (1)
GlaxoSmithKline (5) · ViiV Healthcare (3) · Glaxo Wellcome (2) · Georgetown University (1) · University Hospital, Tours (1) · University of California, San Diego (1)
United States (10) · France (6) · Italy (4) · Spain (4) · United Kingdom (4) · Belgium (3) · Germany (3) · Canada (2) · Portugal (2) · Puerto Rico (2) · Romania (2) · Switzerland (2) · Australia (1) · Austria (1) · Brazil (1)
Princy Kumar, MD (1)
PMID 18383194, PMID 20133266, PMID 21126954, PMID 23741991, PMID 24352352, PMID 31350995
R01MH058076 (1)